RADNOR, Pa., February 9, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. MLYS, a clinical-stage biopharmaceutical company focused on developing drugs to combat diseases caused by abnormally elevated aldosterone, today announced pricing for its increased public offering of 12,000,000 common shares at an initial price of $16.00 known per share. All shares are offered by Mineralys. Gross proceeds from the offering, before deducting subscription discounts and commissions and other offering costs, are expected to be $192.0 million. Shares of Mineralys common stock are expected to trade on the Nasdaq Global Select Market on February 10, 2023 under the ticker symbol “MLYS”. The offering is expected to close on February 14, 2023, subject to the satisfaction of customary closing conditions. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 common shares at the initial offering price less subscription discounts and commissions.

BofA Securities, Evercore ISI, Stifel, Guggenheim Securities, Credit Suisse and Wells Fargo Securities are acting as joint book-running managers for the offering.

Registration statements relating to the offering have been filed with the Securities and Exchange Commission and are effective on February 9, 2023. The offer is made only by means of a prospectus. Copies of the final prospectus, where available, may be obtained from BofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255, by phone at (800) 294-1322 or email at dg.prospectus_requests@bofa.com; Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by phone at (888) 474-0200 or email at ecm.prospectus@evercore.com; or Stifel, Nicolaus & Company, Incorporated, Caution:…